IL6 and chronic kidney disease: Chronic low-grade inflammation, mainly through the IL-6 and the NLRP3 inflammasome signaling pathways, increases the risk of developing anemia, accelerated atherosclerosis, insulin resistance, diabetes mellitus and osteoporosis in CKD [7,8].